get a key
steadybase-$ company ALKS
account_id none on file
legal_name Alkermes plc.
ticker ALKS
cik 1520262
domain alkermes.com
entry_point_account_id none on file
name Alkermes plc
exchange Nasdaq
sector Health Care
hq Dublin 4, Ireland
calls 5 filings 0 executives 7 family 0
why_nownone on file
calls
Our top line results, combined with our continued focus on disciplined operating expense management, resulted in a gap net income of $237.1 million and non-gap net income of $94.3 million for the quarter, which, as I mentioned, excludes the Janssen-backed royalties and associated interest of $197.1 million related to 2022.

Jul 26, 2023 / receipt, needs a key / Ian Brown, CFO | earnings call 2023-07-26 | transcript e5c0da73-40cc-48ae-9445-46f3fabee25b | chars 7024-7348 | segment 7

And from a financial standpoint, we continued our sharp focus on operational efficiency, disciplined expense management, and driving profitability.

Feb 16, 2023 / receipt, needs a key / Rich, other | earnings call 2023-02-16 | transcript 89859b5e-6a8c-4739-8d0a-efa2121e8fa0 | chars 22121-22268 | segment 22

I'm pleased with these results, which reflect the company's progress over the last several years in fueling top-line growth through Alchemy's developed products, coupled with a continued focus on disciplined expense management and operational efficiencies.

Feb 16, 2022 / receipt, needs a key / Ian Brown, CFO | earnings call 2022-02-16 | transcript 129e00a7-83ec-4f30-ab64-b9d6a60a8ef1 | chars 8464-8720 | segment 8

So I think restating the targets really highlights the company's continued commitment to long-term profitability. I think there are margin targets, so revenue matters and expense management matters. I think right now we're really focused on managing driving the profitability through driving the top line through the proprietary products, Vivitrol, Aristar, and Lebalvi, as I mentioned. Vumerit is going to be an important contributor to that as well. And we're very much focused on managing cost structure.

Feb 16, 2022 / receipt, needs a key / Richard, CFO | earnings call 2022-02-16 | transcript 129e00a7-83ec-4f30-ab64-b9d6a60a8ef1 | chars 36796-37303 | segment 37

SG&A expenses for 2020 decreased to $538.8 million from $599.4 million in 2019, reflecting the impact in 2020 of the 2019 restructuring of COVID and ongoing expense management measures during the year.

Feb 11, 2021 / receipt, needs a key / Ian Brown, CFO | earnings call 2021-02-11 | transcript 52010326-8fb5-4317-971b-862b9d05cbf7 | chars 10861-11062 | segment 11

filingsnone on file
executives
Blair C. Jackson Chief Executive Officer - receipt
Ian Brown CFO - receipt
Ian Meredith CEO - receipt
James Robinson President and Chief Operating Officer - receipt
Rich Murray CFO - receipt
Richard Pops CEO - receipt
Richard Potts CEO - receipt
familynone on file
upcoming
2026-10-27 earnings call scheduled webcast / ir
changes
2026-02-25 Chief Executive Officer, appointed sec_8k
2021-01-06 Executive Vice President, appointed sec_8k
2018-03-01 President and Chief Operating Officer, appointed sec_8k
mcp_package_hint
steadybase-$